Text message intervention designs to promote adherence to antiretroviral therapy (ART): A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Finitsis, David J ^a   Pellowski, Jennifer A ^a   Johnson, Blair T ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; ELECTRONIC MEDICAL RECORD; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; META ANALYSIS (TOPIC); MOBILE PHONE; NONHUMAN; NONVERBAL COMMUNICATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONALIZED MESSAGE CONTENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEARCH ENGINE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TEXT MESSAGE INTERVENTION; VIRUS LOAD;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMINDER SYSTEMS; TEXT MESSAGING; TREATMENT OUTCOME;

EID: 84895550412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088166     Document Type: Article

References (64)

1. Sahay S, Reddy K, Dhayarkar S (2011) Optimizing adherence to antiretroviral therapy. Indian J Med Res134: 835-849.
2. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, et al. (2009) Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 49: 651-681.
3. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, et al. (2011) Adherence to highly active antiretroviral therapy (HAART): A meta-analysis. AIDS Behav 15: 1381-1396.
4. Bangsberg DR, Sharon P, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181-1183. (Pubitemid 32549871)
5. Sherr L, Lampe F, Clucas C, Johnson M, Fisher M, et al. (2010) Self-reported non-adherence to ART and virological outcome in a multclinic UK study. AIDS Care, 22: 939-945.
6. Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin AG, et al. (2013) Prevalence of HIV-1 drug resistance in treated patients with viral load .50 copies/mL in 2009: A French nationwide study. J Antimicrob Chemother. Available: doi:10.1093/jac/dkt033.
7. Ferreira JL, Rodrigues R, Lanca AM, Correia de Almeida V, Rocha SQ, et al. (2013) Transmitted drug resistance among people living with HIV/AIDS at major cities of Sao Paulo State, Brazil. Adv Virol. Available: http://dx.doi.org/10.1155/2013/878237.
8. Sinha S, Ahmad H, Shekhar RC, Kumar N, Dar L, et al. (2012) Prevalence of HIV drug resistance mutations in HIV type 1 isolates in antiretroviral therapy naive population from northern India. AIDS Res Treat. doi:10.1155/2012/905823.
9. Thao VP, Le T, Torok EM, Yen NT, Chau TT, et al. (2012) HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. Antivir Ther. doi:10.3851/IMP2092; 10.3851/IMP2092.
10. Friedman SR, Bolyard M, Mateu-Gelabert P, Goltzman P, Pawlowicz MP, et al. (2007) Some data-driven reflections on priorities in AIDS network research. AIDS Behav 11: 641-651. doi 10.1007/s10461-006-9166-7.
11. Johnson BT, Redding CA, DiClemente RJ, Dodge BM, Mustanski BS, et al. (2010). A Network-Individual-Resource model for HIV prevention. AIDS Behav: 204-221. doi: 10.1007/s10461-010-9803-z.
12. Park-Wyllie LY, Kam D, Bayoumi AM (2009) The adherence support gap: The 'ideal' versus 'reality' of antiretroviral adherence support provided by HIV health providers in clinical practice. Ann Pharmacother 43: 1036-1044.
13. World Health Organization (2006) Working together for health: The world health report. Geneva: WHO press.
14. Amico KR, Harman JJ, Johnson BT (2006) Efficacy of antiretroviral therapy adherence interventions: A research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 41: 285-297.
15. Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, et al. (2011) Interventions to increase antiretroviral adherence in sub-saharan Africa: A systematic review of evaluation studies. Lancet Infect Dis 11: 942-951 DOI:10.1016/S1473-3099(11)70181-5.
16. Simoni JM, Frick PA, Pantalone DW, Turner BJ (2003) Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med 11: 185-198.
17. Amico KR, Orrell C (2013) Antiretroviral therapy adherence support: Recommendations and future directions. J Int Assoc Provid AIDS Care. Published online January 18, 2013. doi: 10.1177/1545109712459041.
18. Wise J, Operario D (2008) Use of electronic reminder devices to improve adherence to antiretroviral therapy: A systematic review. AIDS Patient Care STDs 22: 495-504. DOI: 10.1089/apc.2007.0180.
19. Goggin G (2006) Cell phone culture: Mobile technology in everyday life. New York: Routledge. 240 p.
20. Sanou B. Telecommunication Development Bureau, ICT Data and Statistics Division. (2013) The world in 2013: ICT facts and figures. Available: http://www.itu.int/en/ITU-D/Statistics/Documents/facts/ICTFactsFigures2013.pdf. Accessed 12 June 2013.
21. Horvath T, Azman H, Kennedy GE, Rutherford GW (2012) Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. Available: DOI: 10.1002/14651858. CD009756. Accessed 1 May 2012.
22. World Health Organization (2013) Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available: www.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed 1 October 2013.
23. Coomes CM, Lewis MA, Uhrig JD, Furberg RD, Harris JL, et al. (2012) Beyond reminders: A conceptual framework for using short message service to promote prevention and improve healthcare quality and clinical outcomes for people living with HIV. AIDS Care 24: 348-357. doi:10.1080/09540121.2011.608421.
24. Crankshaw T, Corless IB, Giddy J, Nicholas PK, Eichbaum Q, et al. (2010) Exploring the patterns of use and the feasibility of using cellular phones for clinic appointment reminders and adherence messages in an antiretroviral treatment clinic, Durban, South Africa. AIDS Patient Care STDs 24: 729-734. doi:10.1089/apc.2010.0146.
25. Curioso WH, Quistberg DA, Cabello R, Gozzer E, Garcia PJ, et al. (2009) "It's time for your life": How should we remind patients to take medicines using short text messages? AMIA Annu Symp Proc: 129-133.
26. Harris LT, Lehavot K, Huh D, Yard S, Andrasik MP, et al. (2010). Two-way text messaging for health behavior change among human immunodeficiency virus-positive individuals. Telemed J 16: 1024-1029. doi:10.1089/tmj.2010.0050.
27. th International Conference on HIV Treatment and Prevention Adherence, Miami, FL, USA. Available: http://www.iapac.org/ AdherenceConference/Adherence-2013.html. Accessed 12 June 2013.
28. Card N (2012) Applied meta-analysis for social science research. New York: The Guilford Press. 377 p.
29. Johnson BT, Huedo-Medina TB (2012). Meta-analytic statistical inferences for continuous measure outcomes as a function of effect size metric and other assumptions. Technical report EHC-2012-01-0011.R2 for the Agency for Healthcare Research and Quality.
30. Wilson DB (2002). Meta-analysis macros for SAS, SPSS, and Stata [Computer Software]. Available: http://mason.gmu.edu/~dwilsonb/ma.html. Accessed 7 April 2012.
31. Sánchez-Meca J, Marín-Martínez F, Chacón-Moscoso S (2003) Effect-size indices for dichotomized outcomes in meta-analysis. Psychol Methods 8: 448-467. DOI: 10.1037/1082-989X.8.4.448.
32. Huedo-Medina TB, Johnson BT (2011) Estimating the standardized mean difference effect size and its variance from different data sources: A spreadsheet. Storrs, CT, USA: Authors.
33. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327: 557-560. DOI: 10.1136/bmj.327.7414.557.
34. 2 index? Psychol Methods 11: 193-206.
35. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions J Epidemiol Community Health 52: 377-384. (Pubitemid 28438523)
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med: Available: e1000097. doi:10.1371/journal.pmed1000097. Accessed 5 June 2013.
38. da Costa TM, Barbosa BJP, Gomes e Costa DA, Sigulem D, de Fatima Marin H, et al. (2012) Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inform 81: 257-269. doi:10.1016/j.ijmedinf.2011.10.002.
39. Hardy H, Kumar V, Doros G, Farmer E, Drainoni M, et al. (2011) Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy. AIDS Patient Care STDs: 153-161.
40. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, et al. (2010) Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): A randomised trial. The Lancet, 376: 1838-1845. doi:10.1016/S0140-6736(10)61997-6.
41. Musser D (2001) The effect of a technology-linking care (TLC) intervention on HIV/AIDS patients' therapeutic drug regimen adherence. (Unpublished doctoral dissertation, University of Missouri-St. Louis). Available from ProQuest Dissertations and Theses. Accessed 19 March 2012.
42. Mbaugbaw L, Thabane L, Ongolo-Zogo P, Lester RT, Mills EJ, et al. (2012) The Cameroon mobile phone SMS (CAMPS) trial: A randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. PLoS One 7. Available: http://www.plosone.org/Article/info%3Adoi%2F10. 1371%2Fjournal.pone. 0046909. Accessed 23 January 2013.
43. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP et al. (2011). Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: A randomized controlled trial of text message reminders. AIDS 25: 825-834. doi:10.1097/QAD.0b013e32834380c1.
44. Safren SA, Hendriksen ES, Desousa N, Boswell SL, Mayer KH (2003) Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care, 15: 787-793. doi:10.1080/09540120310001618630. (Pubitemid 37494568)
45. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, et al. (2009) Peer support and pager messaging to promote antiretroviral modifying therapy in seattle: A randomized controlled trial. J Acquir Immune Defic Syndr: 52: 465-473.
46. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159-174. (Pubitemid 8054849)
47. rd Ed.) Guilford Press: New York. 482 p.
48. Brion J (2013) The patient-provider relationship as experienced by a diverse sample of highly adherent HIV-infected people. J Assoc Nurses AIDS Care: In press. Available: http://dx.doi.org/10.1016/j.jana.2013.01.006. Accessed 2 July 2013.
49. Russell J, Krantz S, Neville S (2004) The patient-provider relationship and adherence to highly active antiretroviral therapy. J Assoc Nurses AIDS Care 15: 40-47. (Pubitemid 39360634)
50. de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, et al. (2010) Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials. Arch Intern Med, 170(3), 240-250.
51. Mihalko SL, Brenes GA, Farmer DF, Katula JA, Balkrishman R, et al. (2004). Challenges and innovations in enhancing adherence. Controlled Clin Trials 25: 447-457. (Pubitemid 39299155)
52. Samet JH, Sullivan LM, Traphagen ET, Ickovics JR (2001) Measuring adherence among HIV-infected persons: Is MEMS consummate technology? AIDS Behav 5: 21-30. (Pubitemid 35364154)
53. Wilson IB, Carter AE, Berg KM (2009) Improving the self-report of HIV antiretroviral medication adherence: Is the glass half full or half empty? Curr HIV/AIDS rep 6: 177-186.
54. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, et al. (2010) Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28: 1097-1107.
55. Berg KM, Wilson IB, Li X, Arnsten JH (2012) Comparison of antiretroviral adherence questions. AIDS Behav 16: 461-468.
56. Buscher A, Hartman C, Kallen MA, Giordano TP (2011) Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naive, HIV patients. HIV Clin Trials, 12: 244-254. doi:10.1310/hct1205- 244; 10.1310/hct1205-244.
57. Kalichman SC, Amaral CM, Swetzes C, Jones M, Macy R, et al. (2009) A simple single-item rating scale to measure medication adherence: Further evidence for convergent validity. J Int Assoc Provid AIDS Care 8: 367-374. doi:10.1177/1545109709352884; 10.1177/1545109709352884.
58. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr Syndromes 36: 1100-1102. (Pubitemid 38989377)
59. Walsh JC, Mandalia S, Gazzard BG (2002). Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16: 269-277. (Pubitemid 34118574)
60. Paterson DL, Swindells S, Mohr J, Brester M, Vergis E, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann of Intern Medicine, 133: 21-30. (Pubitemid 30432540)
61. Bangsberg DR (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43: 939-41.
62. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS (2007) HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr: 4-8. (Pubitemid 46684437)
63. Lima V, Bangsberg D, Harrigan P, Deeks S, Yip B, et al. (2010) Risk of viral failure declines with duration of suppression on HAART, irrespective of adherence level. J Acquir Immune Defic Syndr 55: 460-465.
64. Mbuagbaw L, van der Kop ML, Lester RT, Thirumurthy H, Pop-Eleches C, et al. (2013). Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ Open 3(12): e003950. doi: 10.1136/bmjopen-2013-003950.